Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | GABRP | O00591 | 1/20 | 0.31 |
| ▸ | GABRD | O14764 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.31 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.31 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.31 |
| ▸ | GABRE | P78334 | 1/20 | 0.31 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.31 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.31 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.31 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22843367 | 0.76 | TAS1R3 (0.30) | — | |
| SCHEMBL3648625 | 0.76 | SMN1; SMN2 (0.35) | NOS3NOS1NOS2DAOSMN1; SMN2 | |
| SCHEMBL6786056 | 0.73 | HTT (0.49) | MEN1NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL30532863 | 0.73 | MPO (0.37) | NPC1RAB9AKDR | |
| SCHEMBL6787588 | 0.72 | MAPT (0.39) | DAOMEN1KMT2A | |
| SCHEMBL6782167 | 0.72 | CYP3A4 (0.39) | DAOMEN1NPC1RAB9AKMT2A | |
| SCHEMBL15629822 | 0.71 | POLB (0.34) | NOS3NOS1NOS2GABRPGABRD | |
| SCHEMBL763959 | 0.70 | ALDH1A1 (0.41) | ELANEGABRA1GABRB2 | |
| SCHEMBL24174576 | 0.70 | NOS3 (0.38) | NOS3NOS2 | |
| SCHEMBL5534465 | 0.69 | TAS1R3 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6723741-B2 | ANALGESICS, SEDATIVES, ANESTHETICS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-04-20 | — | — | US | disclosed |
| US-20030105147-A1 | Benzimidazoles and benzothiazoles and uses thereof | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-06-05 | — | — | US | disclosed |
| US-6498177-B2 | ALPHA 2 ADRENERGIC RECEPTOR AGONIST; ANALGESIC, SEDATIVE AND ANAESTHETIC AGENTS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-12-24 | — | — | US | disclosed |
| US-20020049239-A1 | Novel indole and benzothiazole derivatives | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-04-25 | — | — | US | disclosed |
| US-6303643-B1 | THERAPY OF MIGRAINE HEADACHE, HYPERTENSION, ALCOHOL WITHDRAWAL, DRUG ADDICTION, RHEUMATOID ARTHRITIS, PRESBYOPIA, ISCHEMIC PAIN, SPASTICITY, DIARRHEA, NASAL CONGESTION, AND URINARY INCONTINENCE BY ADMINISTERING BENZOTHIAZOLE DERIVATIVE | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-10-16 | — | — | US | disclosed |
| EP-0900080-A4 | NOVEL INDOLE AND BENZOTHIAZOLE DERIVATIVES | SYNAPTIC PHARMA CORP (US) | 2000-12-13 | — | — | EP | disclosed |
| US-6159998-A | Substituted indoles and uses thereof | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2000-12-12 | — | — | US | disclosed |
| US-6040451-A | USED AS ANALGESIC, SEDATIVE AND ANAESTHETIC AGENTS | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2000-03-21 | — | — | US | disclosed |
| US-5948804-A | ANAESTHETIC PREMEDICATION | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1999-09-07 | — | — | US | disclosed |
| EP-0900080-A1 | NOVEL INDOLE AND BENZOTHIAZOLE DERIVATIVES | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1999-03-10 | — | — | EP | disclosed |
| US-5677321-A | ANESTHETIC PREMEDICATION | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1997-10-14 | — | — | US | disclosed |
| WO-1997031636-A1 | NOVEL INDOLE AND BENZOTHIAZOLE DERIVATIVES | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1997-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049239-A1 | Novel indole and benzothiazole derivatives | ADRB2, ADRB1, CNR2 | ELANE 3261/4885NOS3 327/4885NOS1 321/4885 |
| US-20030105147-A1 | Benzimidazoles and benzothiazoles and uses thereof | ADRB2, BDKRB2, ADRB1 | ELANE 3421/4885NOS3 362/4885NOS1 355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.